Cintia Cercato

May 13, 2024 | nature.com | Ildiko Lingvay |Eric Barros |Helen M. Colhoun |Cintia Cercato |A. Michael Lincoff |Jorge Plutzky

AbstractIn the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI).